NASDAQ:CORT - Corcept Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$13.61 -0.29 (-2.09 %)
(As of 07/19/2018 01:59 AM ET)
Previous Close$13.90
Today's Range$13.51 - $13.95
52-Week Range$11.88 - $25.96
Volume1.85 million shs
Average Volume1.57 million shs
Market Capitalization$1.63 billion
P/E Ratio30.93
Dividend YieldN/A
Beta1.93
Corcept Therapeutics logoCorcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:CORT
CUSIP21835210
Phone650-327-3270

Debt

Debt-to-Equity RatioN/A
Current Ratio5.44
Quick Ratio5.26

Price-To-Earnings

Trailing P/E Ratio30.93
Forward P/E Ratio18.64
P/E GrowthN/A

Sales & Book Value

Annual Sales$159.20 million
Price / Sales9.85
Cash Flow$0.4435 per share
Price / Cash30.69
Book Value$1.67 per share
Price / Book8.15

Profitability

EPS (Most Recent Fiscal Year)$0.44
Net Income$129.12 million
Net Margins75.05%
Return on Equity46.78%
Return on Assets39.56%

Miscellaneous

Employees136
Outstanding Shares115,240,000
Market Cap$1,628.27

The Truth About Cryptocurrencies

Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) issued its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.01. The biotechnology company earned $57.66 million during the quarter, compared to analyst estimates of $58.18 million. Corcept Therapeutics had a return on equity of 46.78% and a net margin of 75.05%. The business's revenue for the quarter was up 108.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.06 EPS. View Corcept Therapeutics' Earnings History.

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Corcept Therapeutics.

What price target have analysts set for CORT?

4 brokers have issued 12-month price targets for Corcept Therapeutics' shares. Their predictions range from $20.00 to $32.00. On average, they anticipate Corcept Therapeutics' share price to reach $28.00 in the next twelve months. This suggests a possible upside of 105.7% from the stock's current price. View Analyst Ratings for Corcept Therapeutics.

What is the consensus analysts' recommendation for Corcept Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Corcept Therapeutics' key competitors?

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the folowing people:
  • Dr. Joseph K. Belanoff M.D., Co-Founder, CEO, Pres & Director (Age 61)
  • Mr. Gary Charles Robb, CFO, Chief Accounting Officer & Sec. (Age 55)
  • Dr. Robert S. Fishman M.D., ? F.C.C.P., Chief Medical Officer (Age 56)
  • Dr. Hazel Hunt Ph.D., Sr. VP of Research
  • Donald E. Laferle, Sr. VP

Has Corcept Therapeutics been receiving favorable news coverage?

Media headlines about CORT stock have trended somewhat positive on Thursday, Accern Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Corcept Therapeutics earned a news impact score of 0.20 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 46.36 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Denali Advisors LLC (0.20%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright, Renee D Gala and Robert S Fishman. View Institutional Ownership Trends for Corcept Therapeutics.

Which institutional investors are selling Corcept Therapeutics stock?

CORT stock was sold by a variety of institutional investors in the last quarter, including Denali Advisors LLC. Company insiders that have sold Corcept Therapeutics company stock in the last year include David L Mahoney, G Leonard Baker Jr and Robert S Fishman. View Insider Buying and Selling for Corcept Therapeutics.

Which institutional investors are buying Corcept Therapeutics stock?

CORT stock was purchased by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB. Company insiders that have bought Corcept Therapeutics stock in the last two years include Gary Charles Robb and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $13.61.

How big of a company is Corcept Therapeutics?

Corcept Therapeutics has a market capitalization of $1.63 billion and generates $159.20 million in revenue each year. The biotechnology company earns $129.12 million in net income (profit) each year or $0.44 on an earnings per share basis. Corcept Therapeutics employs 136 workers across the globe.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]


MarketBeat Community Rating for Corcept Therapeutics (NASDAQ CORT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  316 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  547
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.